Home › Companies › Syndax Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Syndax Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Syndax Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Syndax Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Pierre Legault | 37,294,888 | -- | -- | 21,467,975 | 8,034,588 | Majority: yes |
| Elect Director: Michael A. Metzger | 58,113,110 | -- | -- | 649,753 | 8,034,588 | Majority: yes |
| Proposal 2: Advisory vote on executive compensation: | 55,688,039 | 2,985,350 | 89,474 | -- | 8,034,588 | Majority: yes |
| Proposal 3: Ratification of selection of independent registered public accounting firm: | 66,603,912 | 162,947 | 30,592 | -- | -- | Majority: yes |
| Proposal 4: Approval of the 2026 Plan: | 33,333,263 | 25,392,051 | 37,549 | -- | 8,034,588 | Majority: yes |
| Proposal 5: Approval of the 2026 ESPP: | 58,661,941 | 74,047 | 26,875 | -- | 8,034,588 | Majority: yes |
Source: Syndax Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-10 — read the filing on EDGAR.
Each item below shows how the 257 asset managers that disclosed a Syndax Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Syndax Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Advisory vote on executive compensation:”): 55,688,039 for, 2,985,350 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,610,027 outstanding shares: 63% for, 3% against (66% of the company cast a for/against vote).
The 257 asset managers below cast 94% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,294,320 | 13 | 0 | 0 | For |
| BlackRock | 5,247,690 | 7,821 | 0 | 0 | For |
| State Street | 4,317,121 | 19,403 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,701,749 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 2,341,455 | 0 | 0 | 0 | For |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 2,333,573 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 2,268,423 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,173,230 | 0 | 0 | 0 | For |
| Fidelity | 2,163,315 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,161,610 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,726,437 | 0 | 0 | Against |
| Nuveen | 1,485,688 | 0 | 0 | 0 | For |
| TIAA | 1,440,629 | 0 | 0 | 0 | For |
| Charles Schwab | 1,438,277 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| Aisling Capital Management LP | 1,316,806 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,245,615 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 990,969 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 925,332 | 0 | 0 | Against |
| Palo Alto Investors LP | 864,986 | 0 | 0 | 0 | For |
| Two Sigma | 812,965 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 771,246 | 0 | 0 | 0 | For |
| Northern Trust | 701,360 | 11,912 | 0 | 0 | For |
| Trails Edge Capital Partners, LP | 640,898 | 0 | 0 | 0 | For |
| AQR | 616,607 | 0 | 0 | 0 | For |
Showing the 25 largest of 257 asset managers. See all 257 in the interactive database.
47.2% fund support · no official result
The 65 asset managers below cast 47.2% of the shares they voted on this item FOR (9,779,945 for, 10,944,008 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,760,404 | 3,812,965 | 0 | 0 | Against |
| State Street | 1,905 | 2,677,772 | 0 | 0 | Against |
| Fidelity | 2,054,209 | 700 | 0 | 0 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 0 | 1,440,629 | 0 | 0 | Against |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 1,245,615 | 0 | 0 | Against |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| APIS CAPITAL ADVISORS, LLC | 425,108 | 0 | 0 | 0 | For |
| First Trust | 0 | 417,587 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 254,970 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 180,000 | 0 | 0 | Against |
| Invesco | 0 | 177,689 | 0 | 0 | Against |
| Equitable | 121,726 | 54,760 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 111,585 | 0 | 0 | Against |
| SEI | 87,106 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 5,964 | 71,542 | 0 | 0 | Against |
| ProShares | 0 | 71,013 | 0 | 0 | Against |
| Brighthouse | 29,569 | 28,522 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 57,110 | 0 | 0 | Against |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Michael A. Metzger”): 58,113,110 for, 649,753 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,610,027 outstanding shares: 66% for, 0.8% withheld (66% of the company cast a for/withheld vote).
The 64 asset managers below cast 100% of the shares they voted on this item FOR (20,233,720 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,573,366 | 0 | 3 | 0 | For |
| State Street | 2,679,677 | 0 | 0 | 0 | For |
| Fidelity | 2,054,909 | 0 | 0 | 0 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 1,440,629 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,245,615 | 0 | 0 | 0 | For |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| First Trust | 417,587 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 254,970 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| Invesco | 177,689 | 0 | 0 | 0 | For |
| Equitable | 121,726 | 0 | 54,760 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 111,585 | 0 | 0 | 0 | For |
| SEI | 87,106 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,506 | 0 | 0 | 0 | For |
| ProShares | 71,013 | 0 | 0 | 0 | For |
| Brighthouse | 45,836 | 0 | 12,255 | 0 | For |
| AIG/SunAmerica | 57,110 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 47,079 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Pierre Legault”): 37,294,888 for, 21,467,975 withheld, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,610,027 outstanding shares: 42% for, 24% withheld (66% of the company cast a for/withheld vote).
The 64 asset managers below cast 100% of the shares they voted on this item FOR (14,847,771 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,535,196 | 0 | 38,174 | 0 | For |
| State Street | 5,320 | 0 | 2,674,357 | 0 | Abstain |
| Fidelity | 2,054,209 | 0 | 700 | 0 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 1,440,629 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 1,245,615 | 0 | Abstain |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 417,587 | 0 | Abstain |
| Columbia Threadneedle | 254,970 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 180,000 | 0 | Abstain |
| Invesco | 177,689 | 0 | 0 | 0 | For |
| Equitable | 121,726 | 0 | 54,760 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 111,585 | 0 | Abstain |
| SEI | 0 | 0 | 87,106 | 0 | Abstain |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 5,964 | 0 | 71,542 | 0 | Abstain |
| ProShares | 0 | 0 | 71,013 | 0 | Abstain |
| Brighthouse | 17,314 | 0 | 40,777 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 57,110 | 0 | Abstain |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 0 | 0 | 47,079 | 0 | Abstain |
Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.
99.9% fund support · no official result
The 64 asset managers below cast 99.9% of the shares they voted on this item FOR (20,286,589 for, 12,255 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,573,369 | 0 | 0 | 0 | For |
| State Street | 2,679,677 | 0 | 0 | 0 | For |
| Fidelity | 2,054,909 | 0 | 0 | 0 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 1,440,629 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,245,615 | 0 | 0 | 0 | For |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| First Trust | 417,587 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 254,970 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| Invesco | 177,689 | 0 | 0 | 0 | For |
| Equitable | 176,486 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 111,585 | 0 | 0 | 0 | For |
| SEI | 87,106 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,506 | 0 | 0 | 0 | For |
| ProShares | 71,013 | 0 | 0 | 0 | For |
| Brighthouse | 45,836 | 12,255 | 0 | 0 | For |
| AIG/SunAmerica | 57,110 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 47,079 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.
99.7% Majority: yes · of votes cast
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Ratification of selection of independent registered public accounting firm:”): 66,603,912 for, 162,947 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,610,027 outstanding shares: 75% for, 0.2% against (75% of the company cast a for/against vote).
The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (20,285,485 for, 106 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,573,369 | 0 | 0 | 0 | For |
| State Street | 2,679,571 | 106 | 0 | 0 | For |
| Fidelity | 2,054,909 | 0 | 0 | 0 | For |
| BlackRock | 2,043,092 | 0 | 0 | 0 | For |
| TIAA | 1,440,629 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 1,365,057 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,245,615 | 0 | 0 | 0 | For |
| Charles Schwab | 718,984 | 0 | 0 | 0 | For |
| BNY Mellon | 477,196 | 0 | 0 | 0 | For |
| First Trust | 417,587 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 254,970 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| Invesco | 177,689 | 0 | 0 | 0 | For |
| Equitable | 176,486 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 137,313 | 0 | 0 | 0 | For |
| JPMorgan | 122,648 | 0 | 0 | 0 | For |
| Victory Capital | 111,585 | 0 | 0 | 0 | For |
| SEI | 87,106 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,637 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,506 | 0 | 0 | 0 | For |
| ProShares | 71,013 | 0 | 0 | 0 | For |
| Brighthouse | 45,836 | 0 | 12,255 | 0 | For |
| AIG/SunAmerica | 57,110 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,225 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 47,079 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.
99.8% fund support · no official result
The 3 asset managers below cast 99.8% of the shares they voted on this item FOR (2,341,455 for, 2,892 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Eversept Partners, LP | 2,341,455 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 0 | 0 | 7,400 | 0 | Abstain |
| CLEARWATER INVESTMENT TRUST | 0 | 2,892 | 0 | 0 | Against |
100% fund support · no official result
The 3 asset managers below cast 100% of the shares they voted on this item FOR (2,351,747 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Eversept Partners, LP | 2,341,455 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 7,400 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 2,892 | 0 | 0 | 0 | For |
Ranked by the number of Syndax Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 88,610,027 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.10% |
| 2 | BlackRock | 5.93% |
| 3 | State Street | 4.89% |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3.05% |
| 5 | Eversept Partners, LP | 2.64% |
| 6 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 2.63% |
| 7 | Hood River Capital Management LLC | 2.56% |
| 8 | FRANKLIN ADVISERS INC | 2.45% |
| 9 | Fidelity | 2.44% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.44% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Kynam Capital Management LP | 9.62% | DEF14A |
| Entities affiliated with BlackRock, Inc. | 7.61% | DEF14A |
| STATE STREET CORPORATION | 6.39% | 13G |
| The Goldman Sachs Group | 6.30% | DEF14A |
| Vanguard Capital Management | 5.03% | 13G |
| Point72 Asset Management, L.P. | 2.24% | 13G |
| Michael A. Metzger | 2.22% | DEF14A |
| Luke J. Albrecht | 0.83% | DEF14A |
| Keith A. Goldan | 0.57% | DEF14A |
| Dennis G. Podlesak | 0.35% | DEF14A |
Percentages above are of 88,610,027 shares outstanding, as reported by Syndax Pharmaceuticals, Inc. on its Form 10-Q dated 2026-04-27 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Syndax Pharmaceuticals, Inc.’s 10-Q dated 2026-04-27. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Syndax Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 257 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,555 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Syndax Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-10.
Syndax Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).